The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...

US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...

Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the ...

Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...

Exposures to silica dust, solvents or heavy metals increase the likelihood of developing various forms of myositis, ...

Learn about dermatomyositis and the remarkable journey of Audrey Gouskos. Discover how St. Michael's Hospital has provided ...

The positive predictive value (PPV) of myositis antibodies for diagnosing myositis and its related conditions differs by individual antibody type. Greater diagnostic accuracy is associated with ...

New therapies using monoclonal antibodies against lymphocyte signaling pathways might prove helpful in arresting disease progression. sIBM is often misdiagnosed as polymyositis or other diseases ...

Degenerative disk disease is a progressive condition in which spinal disks deteriorate. Surgery is an option, but less invasive treatments and therapies may also help. Degenerative disk disease is ...

TMA funds projects across the spectrum of myositis diseases for researchers around the globe. We are pleased to announce that in 2024 three of these research projects, totaling nearly half a ...